Last reviewed · How we verify
NCT04570527
Optimized Cardioprotection Therapy in Obese Subjects With CAD
trial testing PCI in Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) in 200 participants. Status unknown.
1 October 2021
Quick facts
| Lead sponsor | Xijing Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 January 2019 |
| Primary completion | 1 October 2021 |
| Estimated completion | 30 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- PCI
Conditions studied
- Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) — all drugs for Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) →
- Obesity — all drugs for Obesity →
- Adiposis; Heart — all drugs for Adiposis; Heart →
Sponsor
Xijing Hospital
Who can join
Adults 20 to 70, any sex, with Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate the efficacy and mechanism of Adipokines Cardiac Protection in Obese Patients With coronary artery disease (CAD).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Exosomes derived from pericardial adipose tissues attenuate cardiac remodeling following myocardial infarction by Adipsin-regulated iron homeostasis.
Man W, Song X, Xiong Z, Gu J, et al · · 2022 · cited 26× · PMID 36172581 · DOI 10.3389/fcvm.2022.1003282 -
Adipsin alleviates cardiac microvascular injury in diabetic cardiomyopathy through Csk-dependent signaling mechanism.
Zhang X, Duan Y, Zhang X, Jiang M, et al · · 2023 · cited 23× · PMID 37237266 · DOI 10.1186/s12916-023-02887-7
Verify or expand the search:
- PubMed search for NCT04570527
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PCI
Trials testing the same drug.
- NCT07130188 — Predictors for ACS and Complexity of CAD · not yet recruiting
- NCT06542653 — Effect of PCI on Clinical Prognosis of Chronic Coronary Artery Occlusion · recruiting
- NCT06050096 — DCB Treatment in CTO Guided by IVUS · unknown
- NCT06214754 — Efficacy and Safety of Intravascular High-pressure Cutting Balloon Catheters for PCI · NA · completed
- NCT05292651 — Optimal Stent Deployment Strategy of Contemporary Stents · NA · recruiting
Other recruiting trials for Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
Currently open trials in the same condition.
- NCT07193693 — Barriers Limiting OCT Penetration in Clinical Practice · recruiting
- NCT04347200 — REGistry of Long-term AnTithrombotic TherApy-1 · recruiting
Other Xijing Hospital trials
Trials by the same sponsor.
- NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
- NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
- NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04570527 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
- Last refreshed: 30 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04570527.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing